Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs
Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs
Paris, October 2, 2023. Sanofi will present new data at the 9th Joint ECTRIMS-ACTRIMS meeting evaluating three investigational treatments for multiple sclerosis (MS) that target the underlying biology of MS to treat the full spectrum of disease and reinforce the commitment to address smoldering neuroinflammation, a key driver of disability progression.
New findings from brain-penetrant and bioactive tolebrutinib, the company’s potentially best-in-disease oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, reinforce the ability of this near-term candidate to reach the central nervous system (CNS) to target smoldering neuroinflammation at its source. Data from frexalimab, the potentially best-in-disease novel second-generation investigational anti-CD40L antibody, and SAR443820, the first-in-class oral investigational brain-penetrant receptor-interacting protein kinase 1 (RIPK1) inhibitor, will also be presented.
Erik Wallstroem, MD, PhDGlobal Head of Neurology Development, Sanofi“Our deep expertise in neuroimmunology has allowed us to explore distinct mechanisms that have the potential to halt this debilitating disease by directly crossing the blood-brain barrier or indirectly inhibiting the upstream immunological processes. Specifically for tolebrutinib, addressing the smoldering neuroinflammation activity within the CNS represents a great unmet need in MS and offers significant potential for limiting the destructive, disabling nature of this disease.”
Abstracts accepted for presentation include: CLICK HERE to see the abstracts
Stay informed with MS information, news and resources. Sign-up Here: https://bit.ly/3NkMIeR